ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Clinuvel Pharmaceuticals (CUV.AU)
Clinuvel Pharmaceuticals share price today, ATLAS forecast and fair value
Healthcare · Biotechnology · Australian Securities Exchange · Australia
A$7.20▲ +2.71%
Prices as of Oct 27, 2026 · AUD
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Clinuvel Pharmaceuticals in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Clinuvel Pharmaceuticals
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Clinuvel Pharmaceuticals a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between A$6.62 and A$7.78; in 9 out of 10, between A$5.73 and A$8.98. Estimated annual volatility is 48%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- A$364M
- Market cap (USD)
- $256M
- P/E ratio
- 10.6
- Dividend yield
- 0.68%
- 52-week high
- A$13.48
- 52-week low
- A$6.62
- Revenue (12 months)
- A$94.0M
- Gross margin
- 83.2%
- Operating margin
- 47.3%
- Net margin
- 36.1%
- Beta
- 0.58
What this means
ATLAS does not publish a fair value for CUV.AU right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks CUV.AU has traded between A$6.62 and A$13.48. Today it is 46.6% below that high and 9% above its low.
On the business: net margin is 36.1%; it trades at 10.6 times earnings.
Its beta is 0.58: it tends to move less than the market.
About the company
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally.
Want to see everything about Clinuvel Pharmaceuticals?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Clinuvel Pharmaceuticals do?
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally.
What is the chance CUV.AU goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, CUV.AU ends the month between A$6.62 and A$7.78.
How big is Clinuvel Pharmaceuticals and what is its P/E ratio?
Clinuvel Pharmaceuticals's market capitalization is A$364M. Its price-to-earnings (P/E) ratio is 10.6: you pay A$10.6 for each A$1.00 of yearly earnings.
Does Clinuvel Pharmaceuticals pay a dividend?
Yes. CUV.AU's current dividend yield is 0.68% at today's price (A$7.20).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer